In addition, tumor penetration together with gross tumor accumulationbetter predicted response to ADC in models of metastatic castrate-resistantprostate cancer as the tumor growth, targeted expression levels, andtumor uptake of the ADC’s companion PET agent demonstrateda correlation between expression, uptake, and ADC efficiency.24 Preclinical PET-imaging can help evaluate noveldomain based anti-MSLN targeting agents by assessing their pharmacokineticsprofiles to ensure improved accumulation in the tumor with minimalaccumulation in normal tissues as compared to antibody-based agents. The gene discussed is MSLN; the disease is cancer.